Skip to main content

Advertisement

Table 1 Main characteristics of the entire study population

From: Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study

Characteristics Patients with IIMs and cancer Patients with CAMa Patients with IIMs without cancer
Number of patients 72 60 545
Myositis subtype, n (%)    
 PM 6 (8.3) 3 (5.0) 92 (16.9)
 DM 63 (87.5) 56 (93.3) 418 (76.7)
 IMNM 3 (4.2) 1 (1.7) 35 (6.4)
 Male, n (%) 26 (36.1) 24 (40%) 168 (30.8)
 Age at myositis onset, mean ± SD years 57.7 ± 14.2 58.0 ± 13.1 47.0 ± 14.1
 Age at cancer diagnosis, mean ± SD years 57.5 ± 13.6 58.4 ± 12.9 NA
 Time from first symptoms to myositis diagnosis, mean ± SD months (n) 12.3 ± 35.6 (72) 7.9 ± 21.9 (60) 22.1 ± 35.1 (512)
 Cancer prior to the onset of myositis, mean ± SD, months (n) 56.1 ± 91.3 (19) 11.8 ± 13.4 (13) NA
 Cancer after the onset of myositis, mean ± SD, months (n) 22.8 ± 42.8 (53) 11.7 ± 12.5 (47) NA
 Follow up, median, IQR, months (n) 20.0, 9.0–45.0 (67) 19.0, 9.0–41.8 (55) 34.0,15.0–63.0 (507)
  1. Abbreviations: n number, CAM cancer-associated myositis, IIMs idiopathic inflammatory myopathies, PM polymyositis, DM dermatomyositis, IMNM immune-mediated necrotizing myopathy, SD standard deviation, IQR interquartile range, NA not applicable
  2. aCAM was defined as cancer occurring within 3 years of the disease onset (before or after), in addition, those who had paraneoplastic features but the interval between the onset of myositis and cancer diagnosis was > 3 years were also considered to have CAM